These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22294375)

  • 1. Overview on the Rule of Five.
    Pollastri MP
    Curr Protoc Pharmacol; 2010 Jun; Chapter 9():Unit 9.12. PubMed ID: 22294375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution.
    Henchoz Y; Bard B; Guillarme D; Carrupt PA; Veuthey JL; Martel S
    Anal Bioanal Chem; 2009 Jun; 394(3):707-29. PubMed ID: 19184676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-like properties and the causes of poor solubility and poor permeability.
    Lipinski CA
    J Pharmacol Toxicol Methods; 2000; 44(1):235-49. PubMed ID: 11274893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data.
    Tinworth CP; Young RJ
    J Med Chem; 2020 Sep; 63(18):10091-10108. PubMed ID: 32324397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solubility and permeability measurement and applications in drug discovery.
    Burton PS; Goodwin JT
    Comb Chem High Throughput Screen; 2010 Feb; 13(2):101-11. PubMed ID: 20053165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Today's drug discovery and the shadow of the rule of 5.
    Young RJ
    Expert Opin Drug Discov; 2023; 18(9):965-972. PubMed ID: 37378429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
    Kuentz M; Imanidis G
    Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of blockbuster drugs under the rule-of-five.
    Giménez BG; Santos MS; Ferrarini M; Fernandes JP
    Pharmazie; 2010 Feb; 65(2):148-52. PubMed ID: 20225662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When poor solubility becomes an issue: from early stage to proof of concept.
    Stegemann S; Leveiller F; Franchi D; de Jong H; Lindén H
    Eur J Pharm Sci; 2007 Aug; 31(5):249-61. PubMed ID: 17616376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico physicochemical parameter predictions.
    Wenlock MC; Barton P
    Mol Pharm; 2013 Apr; 10(4):1224-35. PubMed ID: 23305561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
    Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
    Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of determination of biopharmaceutical properties for development candidate selection.
    Yazdanian M
    Curr Protoc Pharmacol; 2013 Mar; Chapter 9():Unit9.17. PubMed ID: 23456615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of oral bioavailability enhancing formulations during drug discovery.
    Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
    Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery.
    Wuelfing WP; El Marrouni A; Lipert MP; Daublain P; Kesisoglou F; Converso A; Templeton AC
    J Med Chem; 2022 Feb; 65(3):1685-1694. PubMed ID: 35060378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
    Desai PV; Sawada GA; Watson IA; Raub TJ
    Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High throughput screening of pharmacokinetics and metabolism in drug discovery (I)--establishment of assessment system for absorption to compounds with a wide diversity of physical properties].
    Komura H; Kawahara I; Shigemoto Y; Matsuda K; Ano R; Murayama Y; Moriwaki T; Yoshida NH
    Yakugaku Zasshi; 2005 Jan; 125(1):121-30. PubMed ID: 15635283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.